Antibodies for
Immunohistochemistry
COX-2 (SP21)
Rabbit Monoclonal Antibody
Cat. No. Description
Volume
45279 IMPATH COX-2 RTU R (SP21)
50 Tests
44262 COX-2 RTU R (SP21)
7 ml Ready To Use
44545 COX-2 0,1 R (SP21)
100 µl liquid Concentrated
44546 COX-2 1 R (SP21)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Colon Adenocarcinoma
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Cyclooxygenase 2 (COX-2) catalyzes the conversion of arachidonic acid to prostaglandin H2 in the first step in the biosynthesis of prostaglandins,
thromboxanes, and prostacyclins. COX-2 inhibition by nonsteroidal anti-inflammatory agents has been shown to decrease angiogenesis and
tumor growth as well as promote apoptosis. COX-2 overexpression has been associated with increased microvascular density.
Squamous vs. Transitional Carcinoma
COX-2 CK, 34βE12
p63
CK 5
Thrombo-
modulin
CK 7
CK 20
Uroplakin III
Squamous Carcinoma
-
+
+
+
+
-
-
-
Transitional Cell Carcinoma
+
+
+
-/+
+
+
+
+
Reference
1. Sano H, et al. Cancer Res. 1995 Sep 1; 55(17):3785-9.
2. Denkert C, et al. Cancer. 2003 Jun 15; 97(12):2978-87.
92
